Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KDAC inhibitors often exhibit sub-optimal efficacy in the clinic (especially when administered to patients with solid tumors) as well as side effects such as blood thinning, cardiac abnormalities, and nausea/vomiting [28].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“HDAC3 was found to be required for genome maintenance and DNA replication in hematopoietic cells (27, 28); therefore, HDAC3 inhibition is suspected to be responsible for bone marrow toxicity seen with nonselective HDAC inhibitors (29).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [29]
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Histone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
“reason for this could be the pharmacokinetic differences between the drugs.(177) The orally available vorinostat has a short half-life (2 hours) and its time to reach peak plasma concentration is 5.”
BackgroundEpigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Immunomodulatory effects of inulin and its intestinal metabolites
Sheng, W., Ji, G., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224092 · Cited by 170
“In the intestine, if HDAC is overexpressed, the balance of gene expression is disrupted and cell proliferation is abnormal, which eventually leads to tumorigenesis (74).”
BackgroundRecent histone deacetylase inhibitors in cancer therapy
Parveen, R., Harihar, D., & Chatterji, B. P. (2023) · Cancer · doi:10.1002/cncr.34974 · Cited by 171
Tischkowitz, M., Huang, S., Banerjee, S., Hague, J., Hendricks, W. P. D., Huntsman, D. G., Lang, J. D., Orlando, K. A., Oza, A. M., Pautier, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3797 · Cited by 171
“HDACi have been clinically approved for the treatment of several hematologic malignancies but have proved less effective for solid tumors (57).”
BackgroundMechanisms of endocrine therapy resistance in breast cancer
Rasha, F. A., Sharma, M., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111322 · Cited by 145
“Therefore, given high HDAC expression in various solid tumors and the success of current HDACi in combinatorial therapies, development of newer forms of HDACi are currently underway to limit the raised safety concerns and to overcome the limited anti-tumor response in solid tumors (Shah, 2019; Qiu et al., 2013).”
InfluentialThakur, A., Tawa, G. J., Henderson, M. J., Danchik, C., Liu, S., Shah, P., Wang, A. Q., Dunn, G., Kabir, M., Padilha, E. C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00193 · Cited by 112
Guan, X., Wang, H., Ban, W.-W., Chang, Z., Chen, H., Jia, L., & Liu, F. (2020) · Cell Death and Disease · doi:10.1038/s41419-019-2210-0 · Cited by 104
Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis
Chen, F., Gao, Q., Wei, A., Chen, X., Shi, Y., Wang, H., & Cao, W. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00631-9 · Cited by 98
“T-cell lymphomas [65], long term uses of nonspecific”
BackgroundStructural and Functional Changes in Aging Kidneys
Dybiec, J., Szlagor, M., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315435 · Cited by 100
“Fortunately, the FDA has already approved a few DNMT and HDAC inhibitors in oncology [55].”
BackgroundTsimberidou, A. M., Beer, P. A., Cartwright, C., Haymaker, C., Vo, H. H., Kiany, S., Cecil, A., Dow, J., Haque, K., Silva, F. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0238 · Cited by 75
“In one approach, pan-HDAC inhibitors have been developed as anticancer agents; these drugs bring into play additional antitumor activity through inhibition of class I HDACs (HDAC1, 2, 3, and 8) but also introduce mechanism-based hematologic and cardiac toxicity (17, 18).”
BackgroundTargeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 70
“[208] proposed that the catalytic pocket of HDACs can be composed of two main entities: the main pocket that comprises the acetate binding cavity, the substrate-binding tunnel, and the rim of the pocket; and the sub-pockets, such as the side pocket (SP), a lower pocket (LP), and the foot pocket (FP) (review in [209]).”
BackgroundInfluentialPulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00614 · Cited by 66
Current trends in development of HDAC-based chemotherapeutics
Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 60
CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 72
Hearing loss in middle-age persons with Down syndrome.
Evenhuis, H. M., van Zanten, G. A., Brocaar, M. P., & Roerdinkholder, W. H. M. (1992) · PubMed · Cited by 58
Mozzetta, C., Sartorelli, V., & Puri, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.007 · Cited by 67
Vergani, B., Sandrone, G., Marchini, M., Ripamonti, C., Cellupica, E., Galbiati, E., Caprini, G., Pavich, G., Porro, G., Rocchio, I., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01194 · Cited by 60
Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
Sandonà, M., Cavioli, G., Renzini, A., Cedola, A., Gigli, G., Coletti, D., McKinsey, T. A., Moresi, V., & Saccone, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054306 · Cited by 65
Pu, J., Liu, T., Wang, X., Sharma, A., Schmidt‐Wolf, I. G. H., Jiang, L., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00507-5 · Cited by 69
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
Starzer, A. M., Preusser, M., & Berghoff, A. S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221096219 · Cited by 67
Pulya, S., Patel, T. K., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114470 · Cited by 56
Bandolik, J. J., Hamacher, A., Schrenk, C., Weishaupt, R., & Kassack, M. U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123052 · Cited by 57
Zang, H., Qian, G., Zong, D., Fan, S., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2020) · Cancer · doi:10.1002/cncr.32744 · Cited by 51
HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice
Samardzija, M., Corna, A., Gomez-Sintes, R., Jarboui, M. A., Armento, A., Roger, J. E., Petridou, E., Haq, W., Paquet-Durand, F., Zrenner, E., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00653-3 · Cited by 48
“Notably, the clinical data already available [71] would greatly facilitate the repurposing for RP treatment, while the side-effect profile associated with systemic application in cancer therapy would likely be of lesser concern if these drugs were used only locally in the eye.”
BackgroundThe epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 61
“Even approved HDACis have side effects, including cardiotoxicity, sepsis, and myelosuppression [374].”
The effects of histone crotonylation and bromodomain protein 4 on prostate cancer cell lines
Xu, X., Zhu, X., Liu, F., Lu, W., Wang, Y., & Yu, J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-21-53 · Cited by 52
“These drugs can inhibit tumor proliferation, migration, invasion, differentiation, and epithelial–mesenchymal transition in different tumors (17).”
BackgroundEpigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
Zhang, S., Duan, S., Xie, Z., Bao, W., Xu, B., Yang, W., & Zhou, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924817 · Cited by 64
“They can either be acetylated or methylated by histone acetyltransferases (HATs) or histone methyltransferases (HMTs), as well as deacetylated or demethylated by histone deacetylases (HDACs) or histone demethylases (HDMs) (Li et al., 2016; Shah, 2019) (Figure 2B).”
BackgroundHistone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
Zhang, B., Liu, B., Chen, D., Setroikromo, R., Haisma, H. J., & Quax, W. J. (2019) · Cancers · doi:10.3390/cancers11050645 · Cited by 44
“PXD101 and FK228 cause infections and tumor lysis syndrome [28].”
BackgroundEpigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Claveria-Cabello, A., Colyn, L., Arechederra, M., Urman, J. M., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020) · Cells · doi:10.3390/cells9102321 · Cited by 43
“Unfortunately, HDACIs have been shown to carry side effects such as nausea, vomiting, fever, and headache, which can be easily managed [139].”
BackgroundRipamonti, C., Spadotto, V., Pozzi, P., Stevenazzi, A., Vergani, B., Marchini, M., Sandrone, G., Bonetti, E., Mazzarella, L., Minucci, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841716 · Cited by 41
“However, clinical studies with panHDACi revealed multiple adverse events (51).”
BackgroundRaucci, A., Zwergel, C., Valente, S., & Mai, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01677 · Cited by 46
A Perspective of Epigenetic Regulation in Radiotherapy
Qin, P., Weng, K., Li, S., Xu, R. H., Wang, Y., & Wu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.624312 · Cited by 44
“…the first type is DNA methyltransferase inhibitors (DNMTi) (Morel et al., 2017), the second type is histone deacetylase inhibitors (HDACi) (Shah, 2019), and the third type are inhibitors of Enhancer of Zeste Homolog (EZHi) (Italiano et al., 2018), histone methyltransferase inhibitors…”
BackgroundMechanisms of HDACs in cancer development
Zhang, Y., Wang, H., Zhan, Z., Gan, L., & Bai, O. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529239 · Cited by 71
“Although fi rst-generation pan-HDAC inhibitors (HDACis), such as Vorinostat and Romidepsin, have been clinically approved for treating speci fi c lymphomas, their off-target effects and drug resistance issues have limited broader clinical applications (5).”
Xie, Z., Ikegami, T., Ago, Y., Okada, N., & Tachibana, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734268 · Cited by 37
“Accumulating evidence indicates that epigenetic control mediated by HDAC inhibitor(s) (HDACi) plays an important role in tumor progression and even in immune regulation.(11,12) Recent research has shown that in vitro, a pan-HDACi, trichostatin A, or suberoylanilide hydroxamic acid, can robustly expand the M-MDSC popul…”
BackgroundA real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors
Li, W., Fu, Y., & Wang, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05691-2 · Cited by 39
“As evident from pre-approval clinical trials, diarrhea, myelosuppression, and cardiotoxicity stand out as the primary safety considerations linked to the utilization of HDAC inhibitors [3].”
InfluentialAkanbi, C. A., Rotimi, D., Ojo, A., & Ojo, O. (2024) · Toxicology Reports · doi:10.1016/j.toxrep.2024.101885 · Cited by 36
“…examples of histone enzyme inhibitors that exhibit potential for regulating gene expression and developmental processes; however, they can also cause serious side effects, such as gastrointestinal problems and hematological abnormalities, which call for close observation during treatment [100,101].”
Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases
Zhang, L., & Cao, W. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02141-8 · Cited by 33
“Several pan- or class-selective HDAC inhibitors, namely Vorinostat, Romidepsin, Belinostat, and Panobinostat, are approved for treatment of patients with hematological malignancies [54].”
BackgroundEpigenetic modifications of Klotho expression in kidney diseases
Xia, J., & Cao, W. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02044-8 · Cited by 34
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Ramos, L., Truong, S., Zhai, B., Joshi, J., Ghaidi, F., Lizardo, M. M., Shyp, T., Kung, S. H. Y., Rezakhanlou, A. M., Oo, H. Z., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3897 · Cited by 35
“While panobinostat appeared to have higher efficacy in Ewing sarcoma cell lines, this can be attributed to the toxicity of panobinostat, as seen in clinical trials when dose-limiting toxicity has restricted effective use in solid tumors (47).”
Epigenetic‐modifying therapies: An emerging avenue for the treatment of inflammatory skin diseases
Yi, J. Z., & McGee, J. S. (2021) · Experimental Dermatology · doi:10.1111/exd.14334 · Cited by 34
Kawata, M., McClatchy, D. B., Diedrich, J. K., Olmer, M., Johnson, K. A., Yates, J. R., & Lotz, M. (2023) · JCI Insight · doi:10.1172/jci.insight.170513 · Cited by 30
“There are concerns of adverse effects for systemic and long-term administration of HDAC inhibitors to treat OA, including myelosuppression, diarrhea, cardiac effects, and osteoporosis (24, 53, 54).”
BackgroundMoi, D., Bonanni, D., Belluti, S., Linciano, P., Citarella, A., Franchini, S., Sorbi, C., Imbriano, C., Pinzi, L., & Rastelli, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115730 · Cited by 26
Electrical Ventricular Remodeling in Dilated Cardiomyopathy
Mages, C., Gampp, H., Syren, P., Rahm, A., André, F., Frey, N., Lugenbiel, P., & Thomas, D. (2021) · Cells · doi:10.3390/cells10102767 · Cited by 34
Kaczmarek, J. V., Bogan, C. M., Pierce, J. M., Tao, Y. K. K., Chen, S., Liu, Q., Liu, X., Boyd, K. L., Calcutt, M. W., Bridges, T. M., et al. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.14.8 · Cited by 24
“46,47 Belinostat itself is already approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.”
Bauer, N., Balourdas, D.-I., Schneider, J. R., Zhang, X., Berger, L. M., Berger, B., Schwalm, M. P., Klopp, N., Siveke, J. T., Knapp, S., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00427 · Cited by 27
Gatti, M., Raschi, E., Poluzzi, E., Martignani, C., Salvagni, S., Ardizzoni, A., & Diemberger, I. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00485-9 · Cited by 22
Therapeutic approaches to Epstein–Barr virus cancers
Soldan, S. S., Messick, T. E., & Lieberman, P. M. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101260 · Cited by 26
Tahghighi, A., Seyedhashemi, E., Mohammadi, J., Moradi, A., Esmaeili, A., Pornour, M., Jafarifar, K., & Ganji, S. M. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01844-w · Cited by 25
“Valproic acid, a branched short-chain fatty acid, causes the specific degradation of HDAC2 [91, 92].”
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Li, Z., Zhao, C. H., He, G., Wang, Y., Wang, Y., & Ma, X. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117028 · Cited by 20
Li, D., Zhang, Z., Li, Y., Wang, X., Zhong, H., Yang, H., Xi, Y., Liu, H., Shen, A., & Hu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00525 · Cited by 20
Wawruszak, A., Gumbarewicz, E., Okoń, E., Jeleniewicz, W., Czapiński, J., Hałasa, M., Okła, K., Smok-Kalwat, J., Bocian, A., Rivero‐Müller, A., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s210029 · Cited by 20
“The mechanisms of the anticancer activities of individual HDIs differ since these agents act by modifying downstream signaling pathways.(13) These anticancer mechanisms have not been fully resolved, partly as their effects are cell type, dose, and time dependent.”
BackgroundTheodoropoulou, M. A., Mantzourani, C., & Kokotos, G. (2024) · Biomolecules · doi:10.3390/biom14121605 · Cited by 23
McClarty, B., Rodriguez, G., & Dong, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674745 · Cited by 19
“These results indicate that HDAC inhibitor itself could induce some side effects, or even results in toxic outcomes, which could be an impendence in preclinical research and clinical application (Subramanian et al., 2010; Gao et al., 2019; Shah, 2019).”
ResultKumar, K., Das, R., Thapa, B., Rakhecha, B., Srivastava, S., Savita, K., Israr, M., Chanda, D., Banerjee, D., Shanker, K., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117300 · Cited by 19
Bieszczad, B., Garbicz, D., Świtalska, M., Dudek, M. K., Warszycki, D., Wietrzyk, J., Grzesiuk, E., & Mieczkowski, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090851 · Cited by 21
“However, it should be taken under consideration that HDAC inhibitors can cause a number of side effects [81] and their potential use and success in cancer therapy is highly dependent on difficulties to achieve selectivity, decrease toxicity, and reduce the adverse effects [82,83].”
BackgroundAnticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
Tsai, F.-L., Huang, H.-L., Lai, M.-J., Liou, J., Pan, S., & Yang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612588 · Cited by 19
“The FDA approved several HDAC inhibitors for various hematological cancers; however, due to the low potency and undesirable safety profiles of these inhibitors, HDACIs that offer greater efficacy, safety, and tolerability need to be identified [20,21].”
BackgroundCarullo, G., Orsini, N., Piano, I., Pozzetti, L., Papa, A., Fontana, A., Napoli, D., Corsi, F., Marco, B. D., Galante, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00477 · Cited by 20
Adverse drug reaction profiles of histone deacetylase inhibitors
Begum, R., Parsons, J. L., & Jones, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19717-w · Cited by 26
“Clinical trials have revealed the main side effects linked to using HDACIs are myelosuppression, cardiotoxicity, and diarrhoea 37 .”
Nazri, J. M., Οικονομοπούλου, Κ., de Araujo, E. D., Kraskouskaya, D., Gunning, P. T., & Chandran, V. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2177251 · Cited by 17
“In terms of side effects, as single-agents, HDAC inhibitors may cause cardiac arrhythmia; gastrointestinal problems like nausea, vomiting, and anorexia; fatigue; as well as hematological effects such as thrombocytopenia, neutropenia, and anemia [115,152,153].”
BackgroundZhang, Y., Gao, J., Wu, J., Liu, S., Zhang, X., & Lv, X. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129462 · Cited by 18
Elfiky, A. M. I., Ghiboub, M., Yim, A. Y. F. L., Hageman, I., Verhoeff, J., de Krijger, M., van Hamersveld, P. H. P., Welting, O., Admiraal, I., Rahman, S., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab176 · Cited by 18
“7,8 22 As histone acetylation drives gene expression in a cell-specific manner, selective targeting strategies of relevant immune cells is a highly attractive approach.”
Manta, A., Kazanas, S., Karamaroudis, S., Gogas, H. J., & Ziogas, D. C. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026913 · Cited by 31
“An overview of the classification of human HDACs, their cellular localization and their tissue expression is presented in Table 1 [25–28].”
BackgroundInfluentialDual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy
Özgencil, F., Gunindi, H. B., & Eren, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107509 · Cited by 15
The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
Zhang, W., Niu, J., Ma, Y., Yang, X., Cao, H., Guo, H., Bao, F., Ahmed, H. A. W., Chen, Y., & Sun, K. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s240721 · Cited by 14
Ricolinostat is not a highly selective HDAC6 inhibitor
Médard, G., & Sheltzer, J. M. (2023) · Nature Cancer · doi:10.1038/s43018-023-00582-3 · Cited by 15
Cassandri, M., Porrazzo, A., Pomella, S., Noce, B., Zwergel, C., Aiello, F. A., Vulcano, F., Milazzo, L., Camero, S., Pajalunga, D., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02115-y · Cited by 17
“…after HDAC3 silencing in FN-RMS cells could be ascribed, at least in part, to the induction of myogenic differentiation after HDAC3 depletion more ef fi ciently in FN-RMS than FP-RMS cells as we showed previously [29] that could result in differentiating cells notoriously more resistant to IR [51].”
Rare Hereditary Gynecological Cancer Syndromes
Watanabe, T., Soeda, S., Endo, Y., Okabe, C., Sato, T., Kamo, N., Ueda, M., Kojima, M., Furukawa, S., Nishigori, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031563 · Cited by 15
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)
Pojani, E., & Barlocco, D. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210901144658 · Cited by 12
Arcos, I. L., & Ruíz-Camps, I. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.07.026 · Cited by 12
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
José‐Eneriz, E. S., Gimenez-Camino, N., Rabal, O., Gárate, L., Miranda, E., Gómez-Echarte, N., García, F., Charalampopoulou, S., Sáez, E., Vilas‐Zornoza, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49784-y · Cited by 15
“The success of HDACi has been modest in AML 37 , and current HDACi have been associated with clinical toxicity 38 – 40 , some of which are serious or life-threatening, such as severe cardiac toxicity, myelosup-pression and gastrointestinal and hepatic effects 38 .”
BackgroundYang, F., Liu, J., Xu, X.-L., Hu, T., Liu, J., He, Z., Zhao, G., Wei, B., & Ma, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01168 · Cited by 12
Abou‐Zied, H. A., Beshr, E. A. M., Hayallah, A. M., & Abdel-Aziz, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136807 · Cited by 14
Liu, T., Zheng, Y., Zhang, Z., Li, S., Chen, J.-T., Peng, A.-H., & Huang, R. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i7.1278 · Cited by 11
Supercharging CAR-T cells through transcriptional and epigenetic armoring
Qin, D., Lei, Y., Shu, P., Zhang, Y., Loh, Y., Wang, Y., & Li, Q. (2025) · Theranostics · doi:10.7150/thno.107908 · Cited by 17
“…has shown dose-limiting toxicity in clinical trials [183], although they used low-dose SAHA to treat CAR-T cells, achieving a balance between therapeutic efficacy and the drug's safe dosage is challenging because lower doses may reduce efficacy, whereas higher doses increase toxicity [184, 185].”
Ricciardi, N. R., Modarresi, F., Lohse, I., Andrade, N. S., Newman, I. A., Brown, J. M., Borja, C., Marples, B., Wahlestedt, C., & Volmar, C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03373-0 · Cited by 12
“We verified that changes in gene expression were not related to cell death as HDACi have been reported to be acutely myelosuppressive [40].”
BackgroundWang, X., Wang, Z., Wang, Z., Chen, X., Yin, H., Jiang, L., Cao, J., & Liu, Y. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.12.001 · Cited by 10
Drug combination screening as a translational approach toward an improved drug therapy for chordoma
Scheipl, S., Barnard, M., Lohberger, B., Zettl, R., Brčić, I., Liegl‐Atzwanger, B., Rinner, B., Meindl, C., & Fröhlich, E. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00632-x · Cited by 10
“chordomas [36], but there seems to be a role for this class in combination therapy and multitarget inhibition [24, 36].”
BackgroundNakano, M., Ohwada, K., Shindo, Y., Konno, T., Kohno, T., Kikuchi, S., Tsujiwaki, M., Ishii, D., Nishida, S., Kakuki, T., et al. (2022) · Cancers · doi:10.3390/cancers14112584 · Cited by 11
Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal
Boateng, A. T., Abaidoo-Myles, A., Bonney, E. Y., & Kyei, G. B. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0195 · Cited by 14
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment
Hussain, M. S., Zhang, L., Rana, A. J., Maqbool, M., Ashique, S., Khan, Y., Jakhmola, V., Hanbashi, A., Mawkili, W., & Khan, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2533113 · Cited by 11
Zhao, C., Tan, T., Zhang, E., Wang, T., Gong, H., Jia, Q., Liu, T., Yang, X., Zhao, J., Wu, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029670 · Cited by 10
Truong, N., Cottingham, A. L., Dharmaraj, S., Shaw, J. R., Lasola, J. J., Goodis, C. C., Fletcher, S., & Pearson, R. M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10611 · Cited by 9
“9,15,16 A recent study from our lab discovered a beneficial modification to SAHA (SAHA-OH), which significantly improved its concentration-dependent toxicity profile and mitigated organ damage without compromising its anti-inflammatory properties when compared to unmodified SAHA under…”
BackgroundPreclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
Zhong, M., Tan, J., Pan, G., Jiang, Y., Zhou, H., Lai, Q., Chen, Q., Fan, L., Deng, M., Xu, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.780118 · Cited by 9
“In this regard, histone deacetylases (HDACs) represent the most widely studied therapeutic targets, with HDAC inhibitors (HDACi) including chidamide, vorinostat and romidepsin, approved for use in the therapy of cutaneous T-cell lymphoma (23, 30).”
BackgroundAhronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0998 · Cited by 9
“HDAC3 was found to be required for genome maintenance and DNA replication in hematopoietic cells (27, 28); therefore, HDAC3 inhibition is suspected to be responsible for bone marrow toxicity seen with nonselective HDAC inhibitors (29).”
Pytel, W. A., Patel, U., Smalley, J. P., Millard, C. J., Brown, E. A., Pavan, A. R., Wang, S., Kalin, J. H., dos Santos, J. L., Cole, P. A., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08929 · Cited by 11
Ning, Z. (2020) · Translational Breast Cancer Research · doi:10.21037/tbcr.2020.03.06 · Cited by 9
“With regard to safety, chidamide is associated mainly with manageable hematologic side effects and lack of, for example, cardiotoxicity and deep vein thrombosis observed with other HDAC inhibitors (47).”
BackgroundTargeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma
Collier, C. D., Getty, P. J., & Greenfield, E. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_4 · Cited by 10
Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs
Walz, A., Vyver, A. J. V. D., Li, Y., Birtwistle, M. R., Krogan, N. J., & Bouhaddou, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108162 · Cited by 8
Tao, Q., Wei, W., Lv, X., Guo, J. X., Tao, Y., Zhang, M., He, G., Li, Z., Gui, S., & Ma, X. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105992 · Cited by 8
Chang, T.-Y., Nepali, K., Chen, Y., Yang, Y. S. H., Hsu, K., Yen, Y., Pan, S., Liou, J., & Lee, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111485 · Cited by 8
“Our medicinal chemistry program is inclined towards the development of potent class I HDACis via structural optimization of entinostat [18,19].”
BackgroundInfluentialZuo, Y., Zhu, Y., Luo, P., Huang, N., Yao, K., Zhang, K., Wang, N., & Gou, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117852 · Cited by 7
Choosing pan-HDAC or selective HDAC inhibitors for anticancer therapy
Ganai, S. A., Bhat, M. A., & Padder, S. A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104544 · Cited by 8
Bao, W., Zhu, Z., Gao, Y., & Chen, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03291-1 · Cited by 7
“Up to now, several HDACis, such as romidepsin, vorinostat, belinosta, and panobinostat [6], have been approved by the Food and Drug Administration (FDA) for the treatment of hematological malignancies.”
BackgroundTruong, N., Goodis, C. C., Cottingham, A. L., Shaw, J. R., Fletcher, S., & Pearson, R. M. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00119 · Cited by 8
Metadata
- Authors
- Shah, R. R.
- Corresponding author
- Shah, Rashmi R.
- ORCID
- Shah, Rashmi R.
- Venue
- Drug Safety
- Published
- 2019-01-16
- Volume
- 42
- Issue
- 2
- Pages
- 235-245
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2910383661
- Cited by
- 197
- References
- 69
- Citations by year
- 2026: 24 · 2025: 46 · 2024: 26 · 2023: 25 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drug Safety (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, tolerability, adverse drug reactions, myelosuppression, diarrhea, cardiotoxicity, QTc prolongation, atrial fibrillation, ventricular tachyarrhythmia, belinostat, chidamide, panobinostat, romidepsin, vorinostat, HDAC isoform selectivity, solid tumors, hematologic malignancies, T-cell lymphoma, multiple myeloma, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Diseases, Histone Deacetylases, Humans, Hydroxamic Acids, Neoplasms, Sulfonamides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.